Where does Arcutis Biotherapeutics, Inc.'s cash flow data come from?

Every line is extracted from Arcutis Biotherapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Net income	——	——	-$44.32M+77.3%	-$93.27M+53.1%	-$129.72M+40.3%
Stock-based compensation	$41.28M-0.5%	$40.36M-3.3%	$39.7M-3.4%	$39.44M-4.5%	$41.48M+5.4%
Change in accounts receivable	$58.96M+22.2%	$73.16M+54.8%	$56.18M+42.1%	$64.36M+156%	$48.26M+97.9%
Change in inventories	$20.48M—	$7.85M—	$8.11M—	——	——
Change in accounts payable	——	——	-$8.43M—	$7.37M—	$1.65M—
Change in accrued liabilities	$71.03M+121%	$50.04M+56.2%	$39.78M+60.6%	$44.33M+85.9%	$32.15M+231%
Change in other assets	$10.45M+7.0%	$2.01M+112%	$808K—	$3.3M—	$9.77M—
Other working capital changes	-$812K—	-$652K—	-$1.03M—	-$1.24M—	——
Amortization of intangible assets	$2.25M-52.8%	$4.67M+137%	$4.42M+139%	$5.13M-97.3%	$4.76M-97.5%
Net cash from operating activities	——	——	——	——	-$110.94M+44.1%
Capital expenditures	——	——	——	$829K+1,084%	$751K+117%
Purchases of investments	$253.03M+23.4%	$246.99M-3.1%	$175.21M-50.7%	$112.36M-69.8%	$204.98M-29.8%
Proceeds from maturities/sales of investments	$209.77M-25.1%	$227.42M-21.2%	$229.69M-20.1%	$277.01M+4.6%	$280M-16.7%
Net cash from investing activities	-$53.34M-177%	-$30.25M-205%	$38.8M—	$148.83M—	$69.27M—
Repayments of debt	——	$0-100%	$25M-66.7%	$50M0.0%	$75M+200%
Proceeds from issuance of common stock	$1.07M—	$0—	——	——	——
Net cash from financing activities	$7.65M—	$6.97M—	——	——	——
Effect of exchange rate changes on cash	——	——	——	——	——
Net increase (decrease) in cash	-$18.65M+86.4%	-$28.74M-65.4%	-$88.04M—	-$11.84M—	-$136.99M—
Interest paid	$10.67M-41.6%	$10.33M-53.5%	$10.74M-58.1%	$14.35M-44.3%	$18.27M-28.6%
Accretion (Amortization) of Discounts and Premiums, Investments	$1.43M-76.3%	$2.11M-69.5%	$3.2M-56.0%	$4.34M-39.0%	$6.04M-7.9%
Amortization of capitalized software and acquired intangible assets	$2.25M-52.8%	$4.67M+137%	$4.42M+139%	$5.13M-97.3%	$4.76M-97.5%
Operating lease liabilities	-$617K+18.3%	-$680K+7.5%	-$742K-3.8%	-$777K-11.8%	-$755K-11.5%
Increase (Decrease) in Prepaid Expense and Other Assets	$10.45M+7.0%	$2.01M+112%	$808K—	$3.3M—	$9.77M—
Other Noncash Income (Expense)	-$812K—	-$652K—	-$1.03M—	-$1.24M—	——
Payment-in-kind interest	$1.8M-62.6%	$1.76M-67.5%	$3.89M+1.7%	$4.24M+4.9%	$4.82M+19.2%
Proceeds From Sale And Maturity Of Available For Sale Securities	——	——	——	——	$285.06M-24.4%
Proceeds from issuance of common stock and pre-funded warrants, net of issuance costs	——	$0—	$0-100%	$0-100%	$0-100%
Accrued payables for capital expenditures	——	——	——	——	——
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations	——	——	——	——	——
Milestone for intangible asset not yet paid in cash	——	——	——	——	——
Free cash flow	——	——	——	——	-$111.69M+43.8%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where does Arcutis Biotherapeutics, Inc.'s cash flow data come from?: Every line is extracted from Arcutis Biotherapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.